2024.08.26 -

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

Caliway announced that the subject recruitment of CBL-514 Phase 2b study for Dercum’s disease has been initiated. The study results are anticipated in Q4 2025.

Caliway Completed CBL-514 Phase 2b Study for Subcutaneous Fat Reduction with Topline Result Expected in Q4 2024

Caliway announces that the CBL-0204 Phase 2b study was completed successfully at the end of May. The topline results are anticipated in Q4 2024.

Caliway Presents CBL-514 Phase 2 Subcutaneous Fat Reduction Study Results Met All the Endpoints Successfully at AMWC Asia-TDAC 2024

Caliway is pleased to announce that Dr. Peter Peng, Chair of the Taiwan Society for Dermatology and Aesthetic Surgery, presents the results of the Phase II clinical trial of CBL-514, the first-in-class candidate drug developed by Caliway, for localized fat reduction at the AMWC Asia-TDAC 2024.

2024.05.12 -

Caliway Completes the Subject Recruitment in CBL-514 Phase 2b Study for Subcutaneous Fat Reduction

Caliway announces the completion of subject recruitment in the CBL-0205 Phase 2b study, enrolling a total of 173 subjects.

2024.05.11 -

Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention

Caliway is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT.

2024.04.25 -

Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

CBL-0201EFP Phase 2 study demonstrated CBL-514 statistically significant efficacy in reducing cellulite severity scores at 4 and 12 weeks after treatment.

Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum’s Disease

CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum’s disease treatment.

2024.02.15 -

Caliway Received U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum’s Disease

CBL-514 is the first drug to receive Fast Track designation for Dercum’s disease treatment.